Does anyone on this board still think DNDN’s only problem is that the “cost density” of Provenge is impeding reimbursement?
I don't know that ANYONE on this board (the frequent posters) thought that cost density was the ONLY problem. Only that you were jumping to conclusions in leaning too much the other way.